Replies to post #309929 on Avid Bioservices Inc (CDMO)

[biopharm]

..most patients do not experience durable clinical benefit.
...
...

There we have it as it sums up why PS Targeting is required

Very nice to see Dr Jedd Wolchok was involved and Dr Jedd Wolchok in collaborations with Peregrine Pharmaceuticals / PS Targeting which has been shown to limit off target TOXICITIES ....very nice!

Now Ronin Capital Management must be wondering IF they don't amend their game plan and if they lose the battle for BOD seats by 10% or so....it will be because they never thought long investors are deeply rooted and not changing unless it is in writing and filed with SEC that NO HALT to PS Targeting collaborations as originally thought.